海泰新光(688677) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 146,890,114.27, representing a 24.86% increase compared to CNY 117,641,916.58 in the same period last year[3]. - Net profit attributable to shareholders was CNY 46,688,665.42, up 21.45% from CNY 38,442,677.55 year-on-year[3]. - Operating profit for Q1 2025 was ¥53,400,464.56, compared to ¥43,669,497.35 in Q1 2024, reflecting a growth of 22%[12]. - Net profit for Q1 2025 was ¥45,790,558.36, up 21% from ¥37,975,036.47 in Q1 2024[13]. - The company incurred a total operating cost of ¥90,011,178.73 in Q1 2025, an increase from ¥71,244,373.98 in Q1 2024[12]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.39, up from ¥0.32 in Q1 2024[13]. Cash Flow and Investments - The net cash flow from operating activities increased by 61.66%, reaching CNY 63,977,722.34, compared to CNY 39,574,829.10 in the previous year[3]. - Cash flow from operating activities for Q1 2025 was ¥63,977,722.34, significantly higher than ¥39,574,829.10 in Q1 2024[14]. - The company reported a net cash increase of ¥36,416,191.40 in Q1 2025, contrasting with a decrease of ¥159,765,162.08 in Q1 2024[15]. - The company's R&D investment totaled CNY 15,588,599.79, a 4.30% increase from CNY 14,945,675.14 in the same period last year[3]. - Research and development expenses increased to ¥15,588,599.79 in Q1 2025, up from ¥14,945,675.14 in Q1 2024[12]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,547,640,272.85, reflecting a 6.00% increase from CNY 1,460,092,283.49 at the end of the previous year[4]. - The total current assets as of March 31, 2025, amounted to CNY 936,929,623.74, an increase from CNY 851,290,383.20 as of December 31, 2024, representing an increase of approximately 10.1%[10]. - Cash and cash equivalents increased to CNY 560,229,844.98 from CNY 523,890,835.86, reflecting a growth of about 6.9%[11]. - The total liabilities increased to CNY 202,815,067.96 from CNY 154,641,332.66, which is an increase of about 31%[11]. - The company's retained earnings rose to CNY 623,756,903.06 from CNY 577,068,237.64, showing an increase of approximately 8.1%[11]. - The inventory level as of March 31, 2025, was CNY 196,729,965.24, compared to CNY 186,514,537.63 at the end of 2024, marking an increase of about 5.8%[11]. - The company's non-current assets totaled CNY 610,710,649.11, slightly up from CNY 608,801,900.29, reflecting a marginal increase of about 0.3%[11]. - The total equity remained stable at CNY 1,344,825,204.89, with no significant changes reported in the capital structure[11]. Market and Growth Outlook - The company is actively expanding its domestic market, particularly in medical optical products, contributing to revenue growth[7]. - The company anticipates further growth in overseas business revenue as customer demand increases[7]. - The gross profit margin remained stable, with net profit growth being lower than revenue growth due to a decrease in recognized investment income[7]. - The number of ordinary shareholders at the end of the reporting period was 4,446[8]. - The company reported no significant changes in the shareholder structure or participation in margin financing activities during the reporting period[10].